Gut bacteria link vegetable nutrients to cardiometabolic protection
A new microbial pathway may help explain why vegetables so often sit at the center of cardiometabolic advice. Researchers at Karolinska Institutet identified a process in which gut bacteria transform nitrate and non-haem iron from food into dinitrosyl iron complexes, or DNICs, molecules that can enter the body and reach organs including the liver and kidneys.
The work points to a mechanism that is more specific than the usual broad message to “eat more vegetables.” It suggests that some of the benefits tied to beetroot, spinach, rocket, lettuce, beans, whole grains, and other plant foods may depend on a biochemical handoff between diet and the gut microbiota. In experimental systems, higher DNIC levels were associated with lower blood pressure, better vascular function, improved blood sugar control, and less fat accumulation in the liver.
A microbial reaction built from nitrate and iron
Nitrate is abundant in many leafy vegetables and beetroot, while non-haem iron is common in plant-based foods. The investigators found that gut microbes can combine those two ingredients and generate DNICs, a class of molecules that had not been recognized in this context before. Once formed, the complexes were absorbed and detected in tissues, with a particular presence in the liver and kidneys.
The study used mice, cells, bacteria, and human samples, giving the finding a wider biological frame than a single-model experiment would allow. Advanced analytical techniques detected DNICs in multiple tissues. In germ-free mice, the molecules were completely absent. That result is especially important because it ties the chemistry directly to the microbiota rather than to the food compounds alone.
One sentence captures the central biological surprise: without gut microbes, the pathway did not happen.
Experimental models tied DNICs to vascular and metabolic gains
After establishing that DNICs could be generated through microbial activity, the researchers increased DNIC levels in two ways: by giving dietary supplements containing nitrate and iron, or by administering synthetically produced DNIC. In an animal model of cardiovascular and metabolic disease, the higher DNIC exposure was associated with several favorable changes.
Blood pressure fell. Vascular function improved. Blood sugar control got better. Liver fat declined.
Those shifts make physiologic sense in a pathway centered on nitric oxide-related chemistry and iron-nitrosyl signaling, both of which can influence endothelial tone, vascular reactivity, and metabolic stress responses. A better-functioning endothelium can relax blood vessels more effectively, which may help lower pressure and support organ perfusion. In parallel, reduced hepatic fat accumulation fits with a broader cardiometabolic effect rather than an isolated vascular one.
The study does not claim that vegetable intake directly cures disease. It does show that the microbiota can convert food-derived nitrate and iron into biologically active molecules with measurable effects in experimental models.
Why this matters for vegetable-rich diets
Vegetable-heavy diets have long been associated with lower cardiovascular and metabolic risk, but the biological explanation has often been incomplete. The current findings offer a plausible bridge between food composition, gut ecology, and organ-level physiology. Instead of treating vegetables as a generic source of fiber, vitamins, and minerals, the research places nitrate and non-haem iron into a shared chemical pathway that may generate downstream protection.
This also gives a more refined view of interindividual variation. People do not all carry the same gut microbial communities, and the ability to generate DNICs may differ accordingly. In practical terms, two people eating similar diets could produce different amounts of these complexes depending on the microbes present in their intestines. That possibility matters because it may help explain why dietary responses are often uneven in the clinic and in population studies.
The work also raises a therapeutic question that extends beyond nutrition counseling. If DNIC production depends on specific bacterial activity, then diet, microbiota composition, or both could become levers for altering this pathway. For now, that remains a research goal rather than a clinical tool.
Human relevance remains inferential, not proven
The investigators cautioned that much of the work was performed in experimental models, and that warning should stay front and center. The biology is compelling, but the findings do not yet establish how strongly the pathway operates in people under ordinary dietary conditions, or whether measured DNIC levels track with clinical outcomes in human cohorts.
The next step is technical as well as biological: the team wants reliable ways to measure DNIC levels in people. They also want to define how the molecules are produced, how they move through the body, and how they affect different physiological processes once they reach target organs. Those questions matter because a pathway can look convincing in animals and still behave differently in humans, especially when diet, medications, comorbidities, and microbial diversity all interfere with the signal.
A direct human readout is still missing, and without it, the clinical meaning of DNIC remains provisional.
What the field will need to answer next
Future work will need to determine whether dietary patterns can intentionally raise DNIC levels, and whether microbiota-directed strategies can do the same. It will also need to establish whether these molecules can be measured reproducibly enough to serve as biomarkers in human research.
For clinicians, the immediate takeaway is narrower than the headline but still important: vegetable-rich diets may be operating through a more intricate metabolic circuit than previously recognized. The gut is not just extracting calories and fiber from food. In this case, it may be manufacturing compounds with direct effects on blood vessels, liver metabolism, and glucose handling.
The investigators involved collaboration with the University Medical Centre Hamburg-Eppendorf and the Johannes Gutenberg University Medical Centre Mainz in Germany. The work was supported by the Swedish Research Council, the Swedish Heart-Lung Foundation, the Novo Nordisk Foundation, the European Research Council, the Knut and Alice Wallenberg Foundation, Diabetes Wellness Sweden, and Karolinska Institutet. No conflicts of interest were declared.